{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:57:15Z","timestamp":1790121435345,"version":"4.0.1"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and IgG4-related cholangitis are chronic inflammatory diseases of the liver with an autoimmune background. The therapy of autoimmune hepatitis targets the autoreactive immune system and is largely dependent on the use of glucocorticoids and cytostatic drugs. In contrast, the treatment of cholestatic autoimmune liver diseases is restricted to the use of secondary or semi-synthetic bile acids, like ursodeoxycholic acid or obeticholic acid. Although the management of the disease using such drugs works well for the majority of patients, many individuals do not respond to standard therapy. In addition, chronic treatment with glucocorticoids results in well-known side effects. Further, the use of bile acids is a symptomatic therapy that has no direct immunomodulatory effect. Thus, there is still a lot of room for improvement. The use of animal models has facilitated to elucidate the pathogenesis of autoimmune liver diseases and many potential target structures for immunomodulatory therapies have been identified. In this review, we will focus on autoimmune hepatitis for which the first animal models have been established five decades ago, but still a precise treatment for autoimmune hepatitis, as obtainable for other autoimmune diseases such as rheumatoid arthritis or multiple sclerosis has yet to be introduced. Thus, the question arises if our animal models are too far from the patient reality and thus findings from the models cannot be reliably translated to the patient. Several factors might be involved in this discrepancy. There is first and foremost the genetic background and the inbred status of the animals that is different from human patients. Here the use of humanized animals, such as transgenic mice, might reduce some of the differences. However, there are other factors, such as housing conditions, nutrition, and the microbiome that might also play an important role. This review will predominantly focus on the current status of animal models for autoimmune hepatitis and the possible ways to overcome discrepancies between model and patient.<\/jats:p>","DOI":"10.3389\/fimmu.2022.898615","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T09:55:10Z","timestamp":1657619710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?"],"prefix":"10.3389","volume":"13","author":[{"given":"Urs","family":"Christen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Hintermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322","article-title":"Simplified Criteria for the Diagnosis of Autoimmune Hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/981086","article-title":"Challenges in the Diagnosis and Management of Autoimmune Hepatitis","volume":"27","author":"Czaja","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune Hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune Hepatitis\u2013Update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients With Primary Biliary Cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1506330","article-title":"Primary Sclerosing Cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S2468-1253(16)30010-3","article-title":"Advances in Primary Sclerosing Cholangitis","volume":"1","author":"Horsley-Silva","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000362","article-title":"IgG4-Related Disease of the Biliary Tract and Pancreas: Clinical and Experimental Advances","volume":"33","author":"Hubers","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12016-014-8430-2","article-title":"IgG4-Associated Cholangitis: A Comprehensive Review","volume":"48","author":"Hubers","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.05.017","article-title":"Animal Models of Autoimmune Hepatitis","volume":"1865","author":"Christen","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08778-6","article-title":"Animal Models of Autoimmune Liver Diseases: A Comprehensive Review","volume":"58","author":"Liu","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B12","first-page":"99","article-title":"Experimental Chronic Active Hepatitis in Rabbits Following Immunization With Human Liver Proteins","volume":"11","author":"Meyer zum Buschenfelde","year":"1972","journal-title":"Clin Exp Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/hep.1840110106","article-title":"Experimental Autoimmune Hepatitis: Disease Induction, Time Course and T-Cell Reactivity","volume":"11","author":"Lohse","year":"1990","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":":1\u201321","DOI":"10.3390\/ijms22094557","article-title":"Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models","volume":"22","author":"Gerussi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3109\/08830185.2014.921162","article-title":"Pathogen Infection as a Possible Cause for Autoimmune Hepatitis","volume":"33","author":"Christen","year":"2014","journal-title":"Int Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/82161","article-title":"Efficient Presentation of Exogenous Antigen by Liver Endothelial Cells to CD8+ T Cells Results in Antigen-Specific T-Cell Tolerance","volume":"6","author":"Limmer","year":"2000","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200421593","article-title":"The Site of Primary T Cell Activation Is a Determinant of the Balance Between Intrahepatic Tolerance and Immunity","volume":"114","author":"Bowen","year":"2004","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nri981","article-title":"Hepatic T Cells and Liver Tolerance","volume":"3","author":"Crispe","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21379","article-title":"In Vivo Immune Modulatory Activity of Hepatic Stellate Cells in Mice","volume":"44","author":"Chen","year":"2006","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32132","article-title":"Ectopic Expression of Neural Autoantigen in Mouse Liver Suppresses Experimental Autoimmune Neuroinflammation by Inducing Antigen-Specific Tregs","volume":"118","author":"Luth","year":"2008","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.152.7.3245","article-title":"Class I-Restricted Cytotoxic T Lymphocytes are Directly Cytopathic for Their Target Cells In Vivo","volume":"152","author":"Ando","year":"1994","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1691527","article-title":"Immunobiology and Pathogenesis of Hepatocellular Injury in Hepatitis B Virus Transgenic Mice","volume":"248","author":"Moriyama","year":"1990","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2395::AID-IMMU2395>3.0.CO;2-D","article-title":"Failure to Induce Organ-Specific Autoimmunity by Breaking of Tolerance: Importance of the Microenvironment","volume":"28","author":"Limmer","year":"1998","journal-title":"Eur J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.5.2415","article-title":"Break of T Cell Ignorance to a Viral Antigen in the Liver Induces Hepatitis","volume":"165","author":"Voehringer","year":"2000","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90165-U","article-title":"Virus Infection Triggers Insulin-Dependent Diabetes Mellitus in a Transgenic Model: Role of Anti-Self (Virus) Immune Response","volume":"65","author":"Oldstone","year":"1991","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2009.08.001","article-title":"Viral Triggers for Autoimmunity: Is the 'Glass of Molecular Mimicry' Half Full or Half Empty","volume":"34","author":"Christen","year":"2010","journal-title":"J Autoimmun"},{"key":"B27","doi-asserted-by":"publisher","first-page":":1\u201317","DOI":"10.1172\/jci.insight.141462","article-title":"Failure of Thymic Deletion and Instability of Autoreactive Tregs Drive Autoimmunity in Immune-Privileged Liver","volume":"6","author":"Preti","year":"2021","journal-title":"JCI Insight"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.4889","article-title":"DNA Vaccination Breaks Tolerance for a Neo-Self Antigen in Liver: A Transgenic Murine Model of Autoimmune Hepatitis","volume":"169","author":"Djilali-Saiah","year":"2002","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20109","article-title":"A Murine Model of Type 2 Autoimmune Hepatitis: Xenoimmunization With Human Antigens","volume":"39","author":"Lapierre","year":"2004","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600228","article-title":"Transient Expression of Transgenic IL-12 in Mouse Liver Triggers Unremitting Inflammation Mimicking Human Autoimmune Hepatitis","volume":"197","author":"Gil-Farina","year":"2016","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071859","article-title":"Breaking Tolerance to the Natural Human Liver Autoantigen Cytochrome P450 2D6 by Virus Infection","volume":"205","author":"Holdener","year":"2008","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26380","article-title":"Genetic Predisposition and Environmental Danger Signals Initiate Chronic Autoimmune Hepatitis Driven by CD4+ T Cells","volume":"58","author":"Hardtke-Wolenski","year":"2013","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3791\/3644","article-title":"The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice","volume":"60","author":"Hintermann","year":"2012","journal-title":"J Vis Exp"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.06.005","article-title":"Epitope Spreading of the Anti-CYP2D6 Antibody Response in Patients With Autoimmune Hepatitis and in the CYP2D6 Mouse Model","volume":"37","author":"Hintermann","year":"2011","journal-title":"J Autoimmun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaut.2012.11.001","article-title":"Molecular Mimicry Rather Than Identity Breaks T-Cell Tolerance in the CYP2D6 Mouse Model for Human Autoimmune Hepatitis","author":"Ehser","year":"2013","journal-title":"J Autoimmun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2013.05.001","article-title":"Mechanism of Autoimmune Hepatic Fibrogenesis Induced by an Adenovirus Encoding the Human Liver Autoantigen Cytochrome P450 2d6","volume":"44","author":"Hintermann","year":"2013","journal-title":"J Autoimmun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13210","article-title":"Type 1 and Type 2 Autoimmune Hepatitis in Adults Share the Same Clinical Phenotype","volume":"41","author":"Muratori","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":":1\u201319","DOI":"10.3390\/ijms17122007","article-title":"Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know From Animal Models","volume":"17","author":"Christen","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.05.033","article-title":"A Reasoned Approach to the Treatment of Autoimmune Hepatitis","volume":"53","author":"Vergani","year":"2021","journal-title":"Dig Liver Dis"},{"key":"B40","article-title":"Tacrolimus: A Potential New Treatment for Autoimmune Chronic Active Hepatitis: Results of an Open-Label Preliminary Trial","volume":"90","author":"Van Thiel","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.10.018","article-title":"Long-Term Follow-Up of Children and Young Adults With Autoimmune Hepatitis Treated With Cyclosporine","volume":"51","author":"Nastasio","year":"2019","journal-title":"Dig Liver Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.746436","article-title":"Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies","volume":"12","author":"Vuerich","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3753081","DOI":"10.1155\/2018\/3753081","article-title":"The Imbalance Between Foxp3(+)Tregs and Th1\/Th17\/Th22 Cells in Patients With Newly Diagnosed Autoimmune Hepatitis","volume":"2018","author":"Liang","year":"2018","journal-title":"J Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4786-9","article-title":"Treatment of Type 1 Diabetes With Teplizumab: Clinical and Immunological Follow-Up After 7 Years From Diagnosis","volume":"62","author":"Perdigoto","year":"2019","journal-title":"Diabetologia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nri2134","article-title":"CD3-Specific Antibodies: A Portal to the Treatment of Autoimmunity","volume":"7","author":"Chatenoud","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/BOR.0000000000000491","article-title":"How Does Abatacept Really Work in Rheumatoid Arthritis","volume":"30","author":"Bonelli","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a Rescue Treatment in Difficult-to-Treat Autoimmune Hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.433","article-title":"A Case of Difficult-to-Treat Autoimmune Hepatitis Successfully Managed by TNF-Alpha Blockade","volume":"104","author":"Weiler-Normann","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.05.046","article-title":"Infliximab as Rescue Therapy in Paediatric Autoimmune Hepatitis","volume":"59","author":"Rajanayagam","year":"2013","journal-title":"J Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Med (Baltimore)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3323-z","article-title":"Infliximab Leading to Autoimmune Hepatitis: An Increasingly Recognized Side Effect","volume":"59","author":"Yilmaz","year":"2014","journal-title":"Dig Dis Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune Hepatitis and Anti-Tumor Necrosis Factor Alpha Therapy: A Single Center Report of 8 Cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-0348-0620-6_224-1","article-title":"CXCR3 and Its Ligands","volume-title":"Encyclopedia of Inflammatory Diseases","author":"Christen","year":"2015"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12825","article-title":"Review Article: Chemokines as Orchestrators of Autoimmune Hepatitis and Potential Therapeutic Targets","volume":"40","author":"Czaja","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3760\/cma.j.issn.1007-3418.2013.04.014","article-title":"[Investigate Circulating Levels of Chemokines and Evaluate the Correlation Between These Chemokines and Liver Function Indicators in Autoimmune Hepatitis]","volume":"21","author":"Li","year":"2013","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.02.007","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD) Potentiates Autoimmune Hepatitis in the CYP2D6 Mouse Model","volume":"69","author":"Muller","year":"2016","journal-title":"J Autoimmun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.04.009","article-title":"Regurgitation of Bile Acids From Leaky Bile Ducts Causes Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice","volume":"127","author":"Fickert","year":"2004","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20022","article-title":"Spontaneous Cholecysto- and Hepatolithiasis in Mdr2-\/- Mice: A Model for Low Phospholipid-Associated Cholelithiasis","volume":"39","author":"Lammert","year":"2004","journal-title":"Hepatology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14183","article-title":"Effects of Adenovirus-Induced Hepatocyte Damage on Chronic Bile Duct Inflammation in a Sclerosing Cholangitis Mouse Model","volume":"39","author":"Fuchs","year":"2019","journal-title":"Liver Int"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.71","article-title":"Do Viral Infections Protect From or Enhance Type 1 Diabetes and How Can We Tell the Difference","volume":"8","author":"Christen","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nri3311","article-title":"Humanized Mice for Immune System Investigation: Progress, Promise and Challenges","volume":"12","author":"Shultz","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000446","article-title":"Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases","volume":"21","author":"Koboziev","year":"2015","journal-title":"Inflammation Bowel Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27998","article-title":"A Novel \"Humanized Mouse\" Model for Autoimmune Hepatitis and the Association of Gut Microbiota With Liver Inflammation","volume":"62","author":"Yuksel","year":"2015","journal-title":"Hepatology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12843","article-title":"The Induction of Autoimmune Hepatitis in the Human Leucocyte Antigen-DR4 non-Obese Diabetic Mice Autoimmune Hepatitis Mouse Model","volume":"186","author":"Yuksel","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-genom-083115-022438","article-title":"The Microbiome and Human Biology","volume":"18","author":"Knight","year":"2017","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000807","article-title":"The Gut-Liver Axis in Cholangiopathies: Focus on Bile Acid Based Pharmacological Treatment","volume":"38","author":"Cariello","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/cmi.2018.7","article-title":"The Microbiome and Autoimmunity: A Paradigm From the Gut-Liver Axis","volume":"15","author":"Li","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaut.2013.06.013","article-title":"Mucosal Immunity in Liver Autoimmunity: A Comprehensive Review","volume":"46","author":"Trivedi","year":"2013","journal-title":"J Autoimmun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.728723","article-title":"Fecal Microbiota Transplantation Controls Progression of Experimental Autoimmune Hepatitis in Mice by Modulating the TFR\/TFH Immune Imbalance and Intestinal Microbiota Composition","volume":"12","author":"Liang","year":"2021","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7201","article-title":"Translocation of a Gut Pathobiont Drives Autoimmunity in Mice and Humans","volume":"359","author":"Manfredo Vieira","year":"2018","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2017.09.016","article-title":"Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance","volume":"171","author":"Rosshart","year":"2017","journal-title":"Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":":1\u201312","DOI":"10.1126\/science.aaw4361","article-title":"Laboratory Mice Born to Wild Mice Have Natural Microbiota and Model Human Immune Responses","volume":"365","author":"Rosshart","year":"2019","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nri3192","article-title":"The Storm has Cleared: Lessons From the CD28 Superagonist TGN1412 Trial","volume":"12","author":"Hunig","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B75","first-page":"740","article-title":"Storm Forecasting: Additional Lessons From the CD28 Superagonist TGN1412 Trial","volume":"12","author":"Horvath","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181922bd3","article-title":"Animal Models of Sepsis: Why Does Preclinical Efficacy Fail to Translate to the Clinical Setting","volume":"37","author":"Dyson","year":"2009","journal-title":"Crit Care Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein. The Soluble TNF Receptor Sepsis Study Group","volume":"334","author":"Fisher","year":"1996","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90160-M","article-title":"NOD Mouse Colonies Around the World\u2013Recent Facts and Figures","volume":"14","author":"Pozzilli","year":"1993","journal-title":"Immunol Today"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120988","article-title":"Unstressing Intemperate Models: How Cold Stress Undermines Mouse Modeling","volume":"209","author":"Karp","year":"2012","journal-title":"J Exp Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.23736\/S2724-5276.20.06166-6","article-title":"Nutri-Epigenetics: The Effect of Maternal Diet and Early Nutrition on the Pathogenesis of Autoimmune Diseases","volume":"73","author":"Bangarusamy","year":"2021","journal-title":"Minerva Pediatr (Torino)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.737964","article-title":"Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality","volume":"12","author":"Quinn","year":"2021","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12865-020-00380-x","article-title":"Genomic, Microbial and Environmental Standardization in Animal Experimentation Limiting Immunological Discovery","volume":"21","author":"Enriquez","year":"2020","journal-title":"BMC Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-019-1976-2","article-title":"Animal to Human Translation: A Systematic Scoping Review of Reported Concordance Rates","volume":"17","author":"Leenaars","year":"2019","journal-title":"J Transl Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-050724","article-title":"Physiologic and Aberrant Regulation of Memory T-Cell Trafficking by the Costimulatory Molecule CD28","volume":"109","author":"Mirenda","year":"2007","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001708","article-title":"Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies","volume":"3","author":"Waibler","year":"2008","journal-title":"PLoS One"},{"key":"B86","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated Subcutaneous Injections of IL12\/23 P40 Neutralising Antibody, Ustekinumab, in Patients With Relapsing-Remitting Multiple Sclerosis: A Phase II, Double-Blind, Placebo-Controlled, Randomised, Dose-Ranging Study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.03.030","article-title":"Reverse Translation of Failed Treatments can Help Improving the Validity of Preclinical Animal Models","volume":"759","author":"'t Hart","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.03.023","article-title":"Improvement of Preclinical Animal Models for Autoimmune-Mediated Disorders via Reverse Translation of Failed Therapies","volume":"19","author":"'t Hart","year":"2014","journal-title":"Drug Discovery Today"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.898615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T10:48:01Z","timestamp":1676112481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.898615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2022.898615"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.898615","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"article-number":"898615"}}